Abstract Progressive pseudorheumatoid dysplasia (PPD) is a skeletal dysplasia characterized by predominant involvement of articular cartilage with progressive joint stiffness. Here we report genetic characterization of a consanguineous family segregating an uncharacterized from of skeletal dysplasia. Whole-exome sequencing of four affected siblings and their parents identified a loss-of-function homozygous mutation in the WISP3 gene, leading
INTRODUCTION
Rare genetic conditions involving the skeletal system arise through misregulation in the process of skeletal development (cartilage and bone growth) and remain a diagnostic challenge because of the rarity of the disease and the heterogeneity in the phenotypes (Kornak and Mundlos 2003; Krakow and Rimoin 2010; Chen et al. 2016) . Moreover, given the fact that some skeletal phenotypes are driven by several different genes, and that some genes can lead to a variety of different skeletal diseases, achieving a molecular diagnosis can be difficult. Correct diagnosis for progressive pseudorheumatoid dysplasia (PPD) is particularly challenging as it is very rare (∼1 in a million) (Wynne-Davies et al. 1982; Garcia Segarra et al. 2012 ) and has similarities with other disorders (i.e., mucopolysaccharidosis, rheumatoid arthritis, and ankylosing spondylitis) (Spranger et al. 1983; Neerinckx et al. 2015) .
RESULTS

Family Description
Here we report genetic characterization of a consanguineous family segregating PPD. Written informed consent was obtained for all participants. The institutional review boards of the Special Medical Center, Tehran, Iran and Stanford University reviewed the project. The family pedigree is shown in Figure 1A . Affected individuals underwent examination at the Special Medical Center for rare diseases, Tehran, Iran. The patients were asymptomatic at birth, with normal growth, development, and intelligence as well as no facial, joint, and skeletal system deformity. However, the disease started to manifest at 4-6 years of age in affected individuals and progressively worsened (Table 1) . Presenting findings included the enlargement of joints-first in the large joints of the limbs (knees, ankles, and elbow) and then a knobby appearance of the proximal interphalangeal joints of the hands. By the age of 10 yr, a knobby appearance in the metacarpophalangeal and distal interphalangeal joints of the hands was present, as well as the involvement of the spine (mild abnormality). In early adolescence, some affected individuals displayed gait disturbances because of knee deformity and some contracture. In late adolescence and beyond, flexion contracture and stiffness in the large joints had developed (knees, elbows, and hip) and the fingers and toes became short (camptodactylic) ( Table 1) . Moreover, a skeletal survey showed degenerative changes with generalized osteopenia with the presence of unfused epiphyses in the vertebrae. All together, these clinical data indicate a skeletal dysplasia; however, because of heterogeneity in skeletal abnormalities, it was challenging to precisely make a diagnosis for this abnormality. Therefore, we applied a WES approach to identify the casual gene and came up with a precise diagnosis.
Exome-Sequencing Results
WES to a mean coverage of >80× (Individuals 1.2, 2.1, 2.2, 2.3, and 2.4 of Fig. 1 ) was performed (Supplemental Table S1 ). We identified 163,116 variants that are shared in all the family members and have a genotype quality score of >20 (Table 2) . Based on the pedigree, we predicted the disease would follow an autosomal recessive pattern. Thus, we analyzed variants that were homozygous in affected individuals but heterozygous in the healthy parents. Of note, 1064 variants (151 missense variants, 359 variants in 3 ′ UTRs and 5 ′ UTRs, 43 frameshift variants, 34 in-frame deletions and insertions, 43 splicing event-related variants, 276 intergenic variants, 321 intronic variants, 101 synonymous variants, and 12 stop gain, stop lost, and stop retained variants) were identified. We then selected variants with a minor allele frequency (MAF) of <0.01 in public databases: dbSNP Common 144 (Database of Single Nucleotide Polymorphism, NCBI), 1000 Genome project phase 3 (www. 1000genomes.org), Exome Aggregation Consortium version 0.3 (ExAC; http://exac. broadinstitute.org/), NHLBI GO Exome Sequencing Project (ESP; http://evs.gs.washington. edu/EVS/). These filtering steps resulted in identifying 286 homozygous variants, of which 26 are exonic and only one variant was predicted to be pathogenic (stop-gain variant) ( Table 2 ). The identified variant occurs in the exon three of WISP3 gene (WISP3;c.156C>A; p. Cys52 * ), is rare (MAF of 0.0008% in ExAC; 0.04% in dbSNP 144; no homozygotes), and is predicted to be deleterious (Table 3) . We confirmed the homozygosity of this variant by Sanger sequencing (Fig. 1B ) using 5 ′ GGCCTGGAGAAGTGTCAGAT3 ′ and 5 ′ GTCTCGTA CCTAGGCCTGTC3
′ for PCR amplification and 5 ′ GTCTCGTACCTAGGCCTGTC3 ′ as a Sanger sequencing primer. We showed that the variant segregates in the family, as all four affected individuals have the homozygous mutation, whereas their parents are heterozygous (Fig. 1B) .
DISCUSSION
In this study, we employed whole-exome sequencing to identify the underlying genetic variants associated with a rare uncharacterized form of skeletal dysplasia. Abnormalities involving the skeletal system remain a diagnostic challenge because of the heterogeneity of skeletal system diseases. Moreover, given the fact that some skeletal phenotypes are driven by several different genes, and that some genes can lead to a variety of different skeletal diseases, achieving a molecular diagnosis can be quite difficult. To overcome this challenge, we combined the clinical data from a family segregating a rare uncharacterized form of skeletal dysplasia with a comprehensive WES approach. We have sequenced all four affected siblings and their parents to identify the causal mutation associated with this skeletal dysplasia in order to make a better diagnostic. Our study reports a homozygote mutation for rs121908901; WISP3; c.156C>A; p.Cys52 * , which introduces a stop codon in the IGFBP (Hurvitz et al. 1999 ).
WISP3
The WNT1 Inducible Signaling Pathway Protein 3 (WISP3) gene encodes a member of the connective tissue growth factor (CTGF) family of secreted cysteine-rich, glycosylated proteins that play a multitude of roles in cell growth and differentiation (Bork 1993 ). The first clinical link between WISP3 and PPD was demonstrated by linkage studies in consanguineous families segregating PPD, which mapped the candidate region to a 3-cM interval between D6S1594 and D6S432 microsatellite markers on Chromosome 6q22 (el-Shanti et al. 1998; Fischer et al. 1998 ). One year later, Hurvitz et al. (1999) identified mutations in the linkage region, specifically in WISP3, as the strongest candidates to cause this autosomal recessive condition.
The Spectrum of Mutations in WISP3
The WISP3 protein contains a signaling peptide (SP) and four conserved cysteine-rich domains that are differentially affected by mutations (Fig. 2) . Figure 2 shows a schematic representation of the WISP3 protein domains, and Table 4 represents a comprehensive representation of the mutation spectrum of WISP3 in the literature (Table 4 ). The insulin-like growth factor-binding domain (IGFBP) has been shown to bind IGF-1 to inhibit signaling, and mutations within have been shown to sensitize articular chondrocytes to IGF-1, causing hypertrophy and diminished production of collagen types II and IX Repudi et al. 2013) . As shown in Figure 2 , this domain contains the highest number of described deleterious mutations (34%), as well as the most affected families. In contrast, the von Willebrand factor type C module (VWC) domain contains only ∼7% of described mutations and has the least evidence regarding its possible function in PPD. Although not demonstrated in WISP3, the VWC domain has been shown to interact with BMP and TGF-β family members and to promote oligomerization in other related family members (Holbourn et al. 2008) . The thrombospondin domain (TSP) has been identified as a negative regulator of Slug/ Notch1 signaling and thus as an anti-angiogenic factor in breast cancer epithelial cells (Huang et al. 2016) . Suppression of Notch is likely important in chondrocytes as well, given the observation that Notch signaling promotes ossification and osteoarthritis (Hosaka et al. 2013) . This domain contains the second highest number, ∼31% of the described deleterious mutations in PPD. Finally, the carboxy-terminal cystine knot-like domain (CTCK) is a commonly identified motif found in proteins that form dimers and bind a variety of ligands (Isaacs 1995; Holbourn et al. 2008) . For example, in a WISP3-related factor called CCN2 Ye et al. 2010 Ye et al. , 2012 Sun et al. 2012; Yu et al. 2015 China, Italy 9
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Molecular Case Studies the cystine knot domain interacts with BMP-2 to activate a signaling program that promotes mature chondrocytes (Maeda et al. 2009 ). This domain has the third highest number of deleterious mutations at 25%.
In conclusion, our study, in line with previous studies (Hurvitz et al. 1999; Nakamura et al. 2007; Neerinckx et al. 2015; Yu et al. 2015; Rai et al. 2016; Yan et al. 2016) , provides further evidence of the essential role of WISP3 in postnatal skeletal growth and cartilage homeostasis in humans.
METHODS Exome Sequencing and Variant Calling
Exome capture, library preparation, and sequencing, as well as data analysis, were performed as previously described (Reza Sailani et al. 2017) . Briefly, exome capture and library preparation were performed using the Agilent SureSelectXT HumanAllExon V5 (product no. 5190-4631). Two micrograms of gDNA was sheared to a peak size of 150-200 bp using the Covaris instrument. Fragmented genomic DNA was purified using Agencourt AmpPure XP beads (Beckman Coulter) to remove fragments of <100 bp. Then, according to the manufacturer's instructions, the purified DNA fragments were then end-repaired, A-tailed, and ligated to indexing-specific paired-end adaptors using the Agilent SureSelect Library Prep Kit, ILM.
The adaptor-ligated libraries were amplified for five cycles with the SureSelect Primer and the SureSelect Indexing Pre-Capture reverse primer. The PCRs were cleaned using the Agencourt AMPure XP beads. To capture exonic regions, 500 ng of each prepared library was hybridized to biotinylated cRNA oligonucleotides for 24 h at 65°C. The captured libraries were pulled down using Dynabeads MyOne Streptavidin T1 (Invitrogen). A postcapture PCR was then performed to amplify the captured libraries and to add the barcode sequences for multiplex sequencing for 14 cycles. Afterward, amplified libraries were purified with AMPure XP Beads. Qubit fluorometer and Bioanalyzer high-sensitivity chips were used to determine the final concentration of each captured library. One library was prepared per sample. Libraries were pooled in three and were paired-end sequenced on a single Illumina HiSeq lane at the Stanford Center for Genomics and Personalized Medicine according to standard protocols. 
Bioinformatics Analyses
Raw FASTQ files were aligned to the human genome (hg19 version), and SNPs and indels were called using the BINA pipeline (http://www.bina.com). For variant filtering, Golden Helix VarSeq software (http://goldenhelix.com/products/VarSeq/) was used.
Sanger Sequencing
We used 5 ′ GGCCTGGAGAAGTGTCAGAT3 ′ and 5GTCTCGTACCTAGGCCTGTC3 ′ for PCR amplification of the variant sequence. PCR amplification was performed using following reagents: 25 µl REDTaq ReadyMix PCR Reaction Mix (Sigma-Aldrich), 1 µl forward primer (10 µM), 1 µl reverse primer (10 µM), 1 µl DNA (50 ng/µl), and 22 µl of water per PCR reaction. An initial denaturation step for 3 min at 94°was followed by 35 cycles of 30 sec at 94°, 30 sec at 57°, 30 sec at 72°, and the process completed by a final extension for 7 min at 72°. The PCR amplification resulted in a single DNA band on a standard 1% agarose gel and was purified by Agencourt AMPure XP beads (Beckman Coulter, Inc) before submitting for Sanger sequencing. The reverse primer 5 ′ GTCTCGTACCTAGGCCTGTC3 ′ was used as sequencing primer. Sanger sequencing was carried out by the Stanford PAN facility using ABI 3130xl Genetic Analyzer.
ADDITIONAL INFORMATION Data Deposition and Access
The family consented to the genetic study and publication of the genetic and clinical results. The exome-sequencing data have been deposited in the National Center for Biotechnology Information (NCBI) Sequence Read Archive (SRA) (http://www.ncbi.nlm.nih.gov/sra/) under SRA Study SRP106899. The variant was submitted to ClinVar (http://www.ncbi.nlm.nih. gov/clinvar/) and can be found under accession number SCV000607728.
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